MELVILLE, N.Y.--(BUSINESS WIRE)--Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its ICON GS electrosurgical generator and handpiece (J-Plasma system).
The technology utilizes a gas ionization process producing a stable thin focused beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon greater precision, minimal invasiveness and an absence of conductive currents during surgery. Recent engineering improvements include increases in power and efficiency and component miniaturization, making manufacturing easier and more efficient.
Mr. Makrides commented, “Since the 2007 acquisition giving Bovie total ownership of J-Plasma, the Company has dynamically changed and improved the device. By incorporating Bovie’s ICON technology as a platform for J-Plasma, we have enhanced the flexibility of the product as well as its potential applications.”
Management is considering possible uses in several surgical procedures including dermatology and plastic surgery as well as several other surgical specialties.
The Company will be attending and presenting its plasma technology at the second annual International Conference on Plasma Medicine at the Tropicano Riverwalk Hotel, San Antonio, TX. March 16th-20th. According to the conferences website (http://plasma.mem.drexel.edu/icpm-2/), the International Conference on Plasma Medicine brings together plasma scientists, medical doctors, biologists and biochemists to share fascinating results of their research and share latest developments in plasma medicine, a new field at the intersection of plasma science, biology and medicine.
Conference Topics: Fundamentals of interaction between plasma and living systems; plasma sterilization; plasma wounds treatment; plasma blood coagulation; plasma cancer treatment; new applications of plasma in medicine; design of plasma systems for medical applications; physics of plasma discharges in medicine; plasma chemistry in medicine.
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.
This document may contain some forward looking statements, particularly regarding operational prospects in 2009 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.
Contact:
Investor: Buttonwood Advisory Group, Inc. John Aneralla, 1-800-940-9087
